Michael Sherman, MD, chief medical officer at Harvard Pilgrim Health Care, discusses the challenges of moving towards performance-based risk-sharing agreements and where they would work best for certain treatments.
Michael Sherman, MD, chief medical officer at Harvard Pilgrim Health Care, discusses the challenges of moving towards performance-based risk-sharing agreements and where they would work best for certain treatments.
Transcript (slightly modified)
What are the challenges of negotiating performance-based risk-sharing agreements?
We’ve been doing risk-sharing agreements with providers for many years. Pharmaceuticals stand out as being a bit different than all other parts of the care delivery continuum. The fact is there is an existing status quo and just as it’s hard to move away from fee-for-service with providers, moving from pay-for-pills to paying for outcomes feels a bit hard. Part of the reason is that pharmaceutical companies haven’t felt the need or the urgency to move in this direction. Now that we have some successes, I think many of them are seeing them as an opportunity, not just as a threat.
Are there certain treatments or disease states where performance-based, risk-sharing agreements work best?
Absolutely, one of the constraints is the disease state. First, there have to be diseases where there is an outcome measure, like reduced cholesterol, like improved hemoglobin A1C for diabetes, like reduced hospitalization. They need to be things where there are objective measures and where they are not impossible or hard to collect. Also, where there is a clear relationship between the treatment and that measure. For cases where there are multiple drug regimens it may be complicated, in cases where the natural course of the disease may be variable it may be hard to do this, and where the impact is many years outed, it’s very hard to do. I estimate there is probably 20% to 25% of drugs where this is a good approach.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More